Study of OBT076 Associated or Not in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma of the Head and Neck (AdCC_2023-01)
A Phase Ib Study of OBT076 or OBT076 Followed by Balstilimab in Patients With Recurrent or Metastatic (R/M) Adenoid Cystic Carcinoma (AdCC) of the Head and Neck (H&N)
Sponsor: Groupe Oncologie Radiotherapie Tete et Cou
Terminated
toxicity
Other terminated trials from Groupe Oncologie Radiotherapie Tete et Cou
- Squamous Cell Carcinoma of the Head and Neck · Phase PHASE3 · Sep 2024
- Nasopharyngeal Cancers · Phase PHASE3 · Apr 2017
See all terminations from Groupe Oncologie Radiotherapie Tete et Cou
Listed as NCT05930951, this PHASE1 trial focuses on Adenoid Cystic Carcinoma of the Head and Neck and remains terminated or withdrawn. Sponsored by Groupe Oncologie Radiotherapie Tete et Cou, it has been updated 8 times since 2023, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
8 versions recorded-
Jun 2025 — Present [monthly]
Terminated PHASE1
Status: Completed → Terminated
-
Dec 2024 — Jun 2025 [monthly]
Completed PHASE1
Status: Suspended → Completed
-
Sep 2024 — Dec 2024 [monthly]
Suspended PHASE1
-
Aug 2024 — Sep 2024 [monthly]
Suspended PHASE1
Status: Recruiting → Suspended
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE1
▶ Show 3 earlier versions
-
Apr 2024 — Jul 2024 [monthly]
Recruiting PHASE1
-
Jan 2024 — Apr 2024 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Aug 2023 — Jan 2024 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Groupe Oncologie Radiotherapie Tete et Cou
For direct contact, visit the study record on ClinicalTrials.gov .